AMICUS THERAPEUTICS INC. - COMMON STOCK

Amicus Therapeutics Provides EU Regulatory Update for AT-GAA

07 Nov 2022 11:20:00 By Nasdaq GlobeNewswire

Amicus Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Updates

07 Nov 2022 06:00:01 By Nasdaq GlobeNewswire

U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease

28 Oct 2022 15:01:00 By Nasdaq GlobeNewswire

Amicus Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022

27 Oct 2022 06:00:01 By Nasdaq GlobeNewswire

Amicus Therapeutics Announces Participation at World Muscle Society 2022

11 Oct 2022 06:00:00 By Nasdaq GlobeNewswire

Amicus Therapeutics Announces Participation at the 2022 AANEM Annual Meeting

21 Sep 2022 06:00:00 By Nasdaq GlobeNewswire

Amicus Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

08 Sep 2022 06:00:01 By Nasdaq GlobeNewswire

Amicus Therapeutics Announces Second Quarter 2022 Financial Results

04 Aug 2022 06:00:03 By Nasdaq GlobeNewswire

Amicus Therapeutics to Announce Second Quarter 2022 Financial Results on August 4, 2022

26 Jul 2022 06:00:00 By Nasdaq GlobeNewswire

Amicus Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

08 Jun 2022 06:00:01 By Nasdaq GlobeNewswire

Amicus Therapeutics Receives Notification of PDUFA Date Extensions for AT-GAA

10 May 2022 15:01:00 By Nasdaq GlobeNewswire

CORRECTING AND REPLACING -- Amicus Therapeutics Announces First Quarter 2022 Financial Results

09 May 2022 08:15:35 By Nasdaq GlobeNewswire

Amicus Therapeutics Announces First Quarter 2022 Financial Results

09 May 2022 06:00:01 By Nasdaq GlobeNewswire

Amicus Therapeutics to Present at the Bank of America 2022 Healthcare Conference

04 May 2022 06:00:02 By Nasdaq GlobeNewswire

Amicus Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022

26 Apr 2022 06:00:00 By Nasdaq GlobeNewswire

Amicus Announces Issuance of New U.S. Composition of Matter Patent for Galafold® (migalastat), Strengthening Patent Protection Through 2038

19 Apr 2022 06:00:01 By Nasdaq GlobeNewswire

Amicus Therapeutics Announces Positive Long-Term Data from Phase 1/2 Study of AT-GAA in Pompe Disease at the 2022 MDA Clinical & Scientific Conference

16 Mar 2022 06:00:01 By Nasdaq GlobeNewswire

Amicus Therapeutics Announces Presentation and Posters at the 2022 MDA Clinical & Scientific Conference

10 Mar 2022 06:00:01 By Nasdaq GlobeNewswire

Amicus Therapeutics to Present at the Cowen 42nd Annual Health Care Conference

01 Mar 2022 06:00:02 By Nasdaq GlobeNewswire

Amicus Therapeutics Announces Full-Year 2021 Financial Results and Corporate Updates

24 Feb 2022 06:00:02 By Nasdaq GlobeNewswire